Opus Genetics, Inc. - 8-K Filing
Opus Genetics reports Q3 2026 net loss of $46.5 million and announces FDA approval for RYZUMVI® supplemental indication. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $IRD
Read the full article at SEC EDGAR
Part of the story Liquidia Corp - 8-K Filing (3 articles)